Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hyaluronic Acid,Calcium Hydroxyapatite
Therapeutic Area: Dermatology Product Name: HArmonyCa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Innovative Luminera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 07, 2020
Details:
Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® collection of fillers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cutia Therapeutics
Deal Size: $11.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement April 23, 2020
Details:
Cutia will have an exclusive license to obtain regulatory approval and sell AMZEEQ. Foamix is to supply Cutia with the finished licensed products for clinical and commercial use.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Azelaic Acid
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Leo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 02, 2020
Details:
Foamix Pharmaceuticals has entered into a settlement and license agreement to resolve the remaining pending patent litigation involving Finacea® Foam.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
